VERICEL CORP (VCEL) Stock Fundamental Analysis
NASDAQ:VCEL - Nasdaq - US92346J1088 - Common Stock - Currency: USD
Taking everything into account, VCEL scores 5 out of 10 in our fundamental rating. VCEL was compared to 558 industry peers in the Biotechnology industry. VCEL has an average financial health and profitability rating. VCEL shows excellent growth, but is valued quite expensive already. These ratings could make VCEL a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year VCEL was profitable.
In the past year VCEL had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: VCEL reported negative net income in multiple years.
In the past 5 years VCEL always reported a positive cash flow from operatings.
1.2 Ratios
With an excellent Return On Assets value of 0.70%, VCEL belongs to the best of the industry, outperforming 90.32% of the companies in the same industry.
VCEL has a Return On Equity of 1.01%. This is amongst the best in the industry. VCEL outperforms 91.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.7% | ||
| ROE | 1.01% | ||
| ROIC | N/A |
ROA(3y)-1.54%
ROA(5y)-1.26%
ROE(3y)-2.18%
ROE(5y)-1.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 1.25%, VCEL belongs to the best of the industry, outperforming 90.86% of the companies in the same industry.
VCEL has a better Gross Margin (72.54%) than 82.97% of its industry peers.
In the last couple of years the Gross Margin of VCEL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 1.25% | ||
| GM | 72.54% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y1.27%
2. Health
2.1 Basic Checks
VCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VCEL has been increased compared to 1 year ago.
VCEL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for VCEL is higher compared to a year ago.
2.2 Solvency
VCEL has an Altman-Z score of 9.40. This indicates that VCEL is financially healthy and has little risk of bankruptcy at the moment.
VCEL has a better Altman-Z score (9.40) than 85.48% of its industry peers.
VCEL has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
VCEL has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: VCEL outperforms 45.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 9.4 |
ROIC/WACCN/A
WACC8.94%
2.3 Liquidity
VCEL has a Current Ratio of 5.01. This indicates that VCEL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.01, VCEL is in line with its industry, outperforming 53.23% of the companies in the same industry.
A Quick Ratio of 4.58 indicates that VCEL has no problem at all paying its short term obligations.
With a Quick ratio value of 4.58, VCEL perfoms like the industry average, outperforming 50.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.01 | ||
| Quick Ratio | 4.58 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 400.00% over the past year.
Measured over the past 5 years, VCEL shows a small growth in Earnings Per Share. The EPS has been growing by 3.71% on average per year.
The Revenue has grown by 14.81% in the past year. This is quite good.
VCEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.01% yearly.
EPS 1Y (TTM)400%
EPS 3YN/A
EPS 5Y3.71%
EPS Q2Q%-187.5%
Revenue 1Y (TTM)14.81%
Revenue growth 3Y14.95%
Revenue growth 5Y15.01%
Sales Q2Q%2.57%
3.2 Future
The Earnings Per Share is expected to grow by 72.81% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 24.96% on average over the next years. This is a very strong growth
EPS Next Y38.83%
EPS Next 2Y105.64%
EPS Next 3Y96.26%
EPS Next 5Y72.81%
Revenue Next Year20.06%
Revenue Next 2Y22.27%
Revenue Next 3Y23%
Revenue Next 5Y24.96%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 1391.00, VCEL can be considered very expensive at the moment.
90.50% of the companies in the same industry are more expensive than VCEL, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of VCEL to the average of the S&P500 Index (26.92), we can say VCEL is valued expensively.
A Price/Forward Earnings ratio of 54.82 indicates a quite expensive valuation of VCEL.
Based on the Price/Forward Earnings ratio, VCEL is valued cheaper than 89.25% of the companies in the same industry.
VCEL's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.49.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1391 | ||
| Fwd PE | 54.82 |
4.2 Price Multiples
VCEL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. VCEL is cheaper than 90.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 486.02 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates VCEL does not grow enough to justify the current Price/Earnings ratio.
VCEL's earnings are expected to grow with 96.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)35.82
PEG (5Y)374.56
EPS Next 2Y105.64%
EPS Next 3Y96.26%
5. Dividend
5.1 Amount
No dividends for VCEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
41.73
+0.07 (+0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners107.6%
Inst Owner Change1.84%
Ins Owners1.04%
Ins Owner Change10.93%
Market Cap2.10B
Analysts87.14
Price Target60.56 (45.12%)
Short Float %9.27%
Short Ratio8.55
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-31.63%
Min EPS beat(2)-78.61%
Max EPS beat(2)15.34%
EPS beat(4)2
Avg EPS beat(4)-4.91%
Min EPS beat(4)-78.61%
Max EPS beat(4)59.63%
EPS beat(8)6
Avg EPS beat(8)15.42%
EPS beat(12)7
Avg EPS beat(12)22.19%
EPS beat(16)8
Avg EPS beat(16)-5.58%
Revenue beat(2)0
Avg Revenue beat(2)-3.82%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)-3.41%
Revenue beat(4)1
Avg Revenue beat(4)-1.65%
Min Revenue beat(4)-4.23%
Max Revenue beat(4)2.84%
Revenue beat(8)3
Avg Revenue beat(8)0.06%
Revenue beat(12)4
Avg Revenue beat(12)-0.53%
Revenue beat(16)6
Avg Revenue beat(16)-0.84%
PT rev (1m)-6.13%
PT rev (3m)-9.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.85%
EPS NY rev (1m)0%
EPS NY rev (3m)-44.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 1391 | ||
| Fwd PE | 54.82 | ||
| P/S | 8.81 | ||
| P/FCF | N/A | ||
| P/OCF | 36.5 | ||
| P/B | 7.11 | ||
| P/tB | 7.26 | ||
| EV/EBITDA | 486.02 |
EPS(TTM)0.03
EY0.07%
EPS(NY)0.76
Fwd EY1.82%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)1.14
OCFY2.74%
SpS4.74
BVpS5.87
TBVpS5.75
PEG (NY)35.82
PEG (5Y)374.56
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.7% | ||
| ROE | 1.01% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 1.25% | ||
| GM | 72.54% | ||
| FCFM | N/A |
ROA(3y)-1.54%
ROA(5y)-1.26%
ROE(3y)-2.18%
ROE(5y)-1.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y1.27%
F-Score5
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 942% | ||
| Cap/Sales | 26.9% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 1437.95% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.01 | ||
| Quick Ratio | 4.58 | ||
| Altman-Z | 9.4 |
F-Score5
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)649.08%
Cap/Depr(5y)464.88%
Cap/Sales(3y)15.17%
Cap/Sales(5y)10.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)400%
EPS 3YN/A
EPS 5Y3.71%
EPS Q2Q%-187.5%
EPS Next Y38.83%
EPS Next 2Y105.64%
EPS Next 3Y96.26%
EPS Next 5Y72.81%
Revenue 1Y (TTM)14.81%
Revenue growth 3Y14.95%
Revenue growth 5Y15.01%
Sales Q2Q%2.57%
Revenue Next Year20.06%
Revenue Next 2Y22.27%
Revenue Next 3Y23%
Revenue Next 5Y24.96%
EBIT growth 1Y25.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2130.55%
EBIT Next 3Y249.59%
EBIT Next 5Y172.93%
FCF growth 1Y-176.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y160.69%
OCF growth 3Y26.05%
OCF growth 5YN/A